Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Crowdstrike Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Crowdstrike Holdings Inc trades at $186.11 (market cap $190.60B). The key difference: Crowdstrike Holdings Inc is far larger — about 4.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CRWD | |
|---|---|---|
Market Cap | $39.89B | $190.60B |
Sector | Health | Technology |
52-Week High | $491.22 | $199.38 |
52-Week Low | $278.09 | $87.56 |
Enterprise Value | $38.15B | $186.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CrowdStrike (CRWD) trades at $187.18, down 5.66% in the last session, following its recent 4-for-1 stock split. The stock exhibits a bullish technical trend with strong moving average signals, though RSI levels suggest overbought conditions. Fundamentally, the company shows robust revenue growth, reaching $3.95 billion in 2025, and has beaten earnings estimates for three consecutive quarters. However, valuation multiples remain elevated with a P/E of 765.02, and net income margins are negative. Analyst sentiment is overwhelmingly positive, with 76% recommending a buy.
The outlook for CRWD is supported by strong demand in AI-driven cybersecurity, but high valuation and intense competition pose risks. Revenue growth acceleration and market leadership in zero-trust security present opportunities, though profitability challenges and premium pricing require careful monitoring. The consensus price target of $184.40 suggests limited near-term upside from current levels, indicating a balanced risk-reward profile for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
